

# R W Paterson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2094321/publications.pdf>

Version: 2024-02-01

27  
papers

1,959  
citations

430442

18  
h-index

500791

28  
g-index

30  
all docs

30  
docs citations

30  
times ranked

3531  
citing authors

#	ARTICLE	IF	CITATIONS
1	Amyloid processing in <sc>COVID</sc>â€19â€associated neurological syndromes. Journal of Neurochemistry, 2022, 161, 146-157.	2.1	35
2	CSF biomarkers for dementia. Practical Neurology, 2022, 22, 285-294.	0.5	3
3	Mass spectrometry analysis of tau and amyloidâ€beta in iPSCâ€derived models of Alzheimerâ€™s disease and dementia. Journal of Neurochemistry, 2021, 159, 305-317.	2.1	8
4	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. Journal of Internal Medicine, 2021, 290, 583-601.	2.7	54
5	A blood miRNA signature associates with sporadic Creutzfeldt-Jakob disease diagnosis. Nature Communications, 2020, 11, 3960.	5.8	20
6	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimerâ€™s disease. Clinical Mass Spectrometry, 2019, 14, 74-82.	1.9	9
7	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
8	SILK studies â€ capturing the turnover of proteins linked to neurodegenerative diseases. Nature Reviews Neurology, 2019, 15, 419-427.	4.9	37
9	CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. Annals of Clinical and Translational Neurology, 2018, 5, 162-171.	1.7	30
10	Significant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy. Clinical Neurology and Neurosurgery, 2016, 144, 64-66.	0.6	1
11	A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimerâ€™s disease pathology. Translational Psychiatry, 2016, 6, e952-e952.	2.4	46
12	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2016, 11, 3.	4.4	236
13	Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology, 2016, 86, 829-835.	1.5	170
14	Do cerebrospinal fluid transfer methods affect measured amyloid Î²42, total tau, and phosphorylated tau in clinical practice?. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 380-384.	1.2	5
15	Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Molecular Neurodegeneration, 2015, 10, 64.	4.4	121
16	A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1240-1247.	0.9	196
17	Clinical relevance of serum antibodies to extracellular<i>N</i>-methyl-d-aspartate receptor epitopes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 708-713.	0.9	97
18	Dissecting IWG-2 typical and atypical Alzheimerâ€™s disease: insights from cerebrospinal fluid analysis. Journal of Neurology, 2015, 262, 2722-2730.	1.8	39

#	ARTICLE	IF	CITATIONS
19	Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. <i>Translational Psychiatry</i> , 2014, 4, e419-e419.	2.4	39
20	Biomarker Modelling of Early Molecular Changes in Alzheimer's Disease. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 213-227.	1.6	4
21	Biomarkers in dementia: clinical utility and new directions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1426-1434.	0.9	119
22	Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 625-630.	0.9	106
23	Subacute peripheral and optic neuropathy syndrome with no evidence of a toxic or nutritional cause. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1389-1393.	0.6	4
24	Identification of an important potential confound in CSF AD studies: aliquot volume. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 2311-7.	1.4	37
25	Recurrent Stereotyped Episodes in Cerebral Amyloid Angiopathy: Response to Migraine Prophylaxis in Two Patients. <i>Cerebrovascular Diseases Extra</i> , 2013, 3, 81-84.	0.5	12
26	Career mentorship for young neurologists in Europe. <i>Neurology</i> , 2012, 79, 381-383.	1.5	0
27	Diagnosis and treatment of rapidly progressive dementias. <i>Neurology: Clinical Practice</i> , 2012, 2, 187-200.	0.8	68